Fundraising Fox
Lqttrx
Founded 2019 · 34 employees on LinkedIn · 5 known investors
Find your way into Lqttrx
Sign up to see every warm intro you have to Lqttrx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lqttrx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases. Its lead compound, THRV-1268, is in a Phase 2/3 clinical study for Long QT Syndrome Type 2.
Founders & leadership
PF
Paul F. TruexChairman of the Board & Chief Executive OfficerChairman of the Board & Chief Executive Officer at Thryvtrx
AS
Amy SehnertChief Medical Officer at Thryvtrx
Investors · 5
Frequently asked questions
- What does Lqttrx do?
- Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases. Its lead compound, THRV-1268, is in a Phase 2/3 clinical study for Long QT Syndrome Type 2.
- Who are Lqttrx's investors?
- Lqttrx's investors include Amzak Health, adMare BioInnovations, Alexandria, CTI Life Sciences Fund L.P., Lumira Ventures.